COMBINATION_PRODUCT · Unmapped registry intervention
Empagliflozin+Linagliptin+Metformin
Find medicine records ·
Find other trials using this name
Clinical trial
Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
NCT06862739
Drugs and interventions used in this trial
1 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
No matching interventions in this trial.
Study at a glance
Registry-backedGlycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE4
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Diabetes Mellitusverified · MONDO: diabetes mellitus
Type 2 DMunresolved
Interventions
Empagliflozin+Linagliptin+MetforminCOMBINATION_PRODUCT
Sponsors & collaborators
Nabiqasim Industries (Pvt) Ltdlead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06862739 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.